Schedule III Aftershocks: How Rescheduling Is Reshaping the Business of Cannabis

Schedule III Aftershocks: How Rescheduling Is Reshaping the Business of Cannabis

The ink on the federal rescheduling order is barely dry, and already the cannabis industry is feeling the tremors. Last month, the Department of Justice placed state-licensed medical cannabis products in Schedule III of the Controlled Substances Act — an action that technically changed nothing about what's legal where, but is rapidly changing everything about how cannabis companies operate, report earnings, and plan their futures.

Nowhere is that transformation more visible than in the quarterly earnings releases hitting markets this month. Trulieve, one of the country's largest multistate operators, reported first-quarter 2026 results showing $286.8 million in revenue and a 59% gross margin, alongside net income attributable to common shareholders of $2.4 million. For a company that spent years hemorrhaging cash under the punishing weight of Section 280E — which barred cannabis businesses from deducting normal business expenses — even a slim profit is a statement of arrival. The company also generated $56 million in operating cash flow and $42 million in free cash flow, figures that would once have been unthinkable in an industry perpetually starved of capital. Trulieve pointedly filed applications with the Drug Enforcement Agency to register its 206 state-licensed retail locations under the new framework, a bureaucratic move that signals just how seriously operators are treating the rescheduling as a genuine inflection point.

Curaleaf, meanwhile, reported Q1 net revenue of $324.2 million — up 6% year-over-year — with international revenue surging 35% to $47.2 million and net income of $70.1 million. The company's international arm, which serves European medical markets, has become a crown jewel at a moment when domestic pricing pressure continues to compress margins. Curaleaf's results make clear that operators with a foot in both hemispheres are finding breathing room that purely domestic players cannot access.

North of the border, Cronos Group posted first-quarter 2026 revenue of $45.2 million, a 40% year-over-year increase, with net income of $15.7 million. For a company that spent years navigating an awkward position — licensed in Canada, selling globally, but hamstrung by U.S. restrictions — the current environment is as favorable as it has ever been.

That said, the sector's structural challenges have not evaporated with a single federal order. Cannabis benchmarks data shows the U.S. Cannabis Spot Index at $1,081 per pound, with the New Jersey market seeing an 8.1% price drop as greenhouse and indoor flower both face downward pressure. Oversupply in mature markets is a problem no policy change can fix overnight, and operators in states like Michigan and California continue to operate in environments where prices have fallen to levels that threaten cultivator profitability.

The consumer side of the market is also undergoing a quiet restructuring. According to Flowhub's cannabis industry data, average cart sizes have declined from 2.9 to 2.7 items over the past 24 months, while online carts average 3.9 items. Shoppers are visiting dispensaries more frequently but spending more intentionally, a behavioral shift that rewards operators with strong digital infrastructure and loyalty programs. Pre-rolls are leading growth at the product level, with $4.1 billion in annual sales and 12% year-over-year growth, driven largely by the infused pre-roll category, where live resin and other premium concentrates are commanding premium prices in a market otherwise under deflationary pressure.

One storyline the earnings reports don't fully capture: the 280E relief is only just beginning to flow through balance sheets. Because the Schedule III order took effect mid-fiscal-year and the IRS has been directed to consider retroactive relief going back to the years operators were subject to the tax, companies are still waiting on formal guidance about how much they may ultimately be owed. Legal observers have described this as potentially one of the largest single windfalls in the industry's history — or a bureaucratic labyrinth that takes years to navigate. Either way, it is shaping capital allocation decisions right now.

Germany's cannabis import market also reflected the global demand expansion, with 50,539 kilograms of medical cannabis imported in Q1 2026, more than half of it supplied by Canadian operators. For Cronos and Curaleaf, which have both invested heavily in EU-GMP-certified production, the European medical market looks less like a hedge and more like a genuine growth engine.

The mood among cannabis executives this spring is cautiously optimistic in a way the industry hasn't felt in years. Rescheduling has not solved the fundamental economics of a fragmented, overtaxed, still-federally-complicated market, but it has given operators something they have lacked since the first dispensary opened: the sense that the federal wind might finally be at their backs. What happens at the DEA's June 29 hearing on full rescheduling will determine whether that wind is a breeze or a gale.